NCI Definition: A rare glial neoplasm more commonly found in young adults. It is characterized by tumor cells with characteristics suggestive of an astrocytic origin (positive for GFAP), arranged perivascularly. The cells have broad, non-tapering processes radiating towards a central blood vessel. The biologic behavior of astroblastomas is variable, so no WHO grade has been established, yet. (Adapted from WHO.) 
Astroblastomas most frequently harbor alterations in TSC2, TP53, TERT, SOX9, and SETD2 .
TSC2 R1409W, TSC2 Mutation, TP53 c.217-c.1178 Missense, TP53 R175H, and TP53 Mutation are the most common alterations in astroblastoma .
There is 1 clinical trial for astroblastoma, of which 1 is open and 0 are completed or closed. Of the trial that contains astroblastoma as an inclusion criterion, 1 is phase 1 (1 open).
Novottf-100a device, bevacizumab, and temozolomide are the most common interventions in astroblastoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.